Yauheniya Baranchykava: Changing Lives Through Innovation in Hemophilia Care
Yauheniya Baranchykava, Hemofilia Squad Lead at Roche, shared a post on LinkedIn:
“Change the lives of people with hemophilia. That is our purpose.
This week we had the privilege of being part of the LATAM Hemophilia Meeting, along with medical specialists from all over Latin America committed to bringing the best science to their patients.
A meeting where knowledge is shared, experiences multiply and the objective is always the same: how do we get more people to access care that really transforms their lives?
Team Chile is committed to bringing science to our medical community.
Because we are convinced: the best science must reach our doctors and, through them, our patients.
Innovation in hemophilia goes far beyond reducing bleeding.
We are talking about children who can go to school without fear, adults who work, families who breathe easier.
Roche Chile’s commitment to hemophilia is real, it is continuous and it is growing.
Thanks to LATAM team, Carolina Ocampo, Josue Hidalgo G Andrea, Morales Heerlein, and their teams to make it possible and team Peru to receive us.
It was amazing!”

Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian